Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
09 oct. 2020 16h01 HE
|
Retrophin, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal...
Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
27 déc. 2018 08h00 HE
|
Retrophin, Inc.
SAN DIEGO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial...
Retrophin to Present at the Jefferies 2018 London Healthcare Conference
07 nov. 2018 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2018 London Healthcare...
Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018
05 oct. 2018 16h01 HE
|
Retrophin, Inc.
SAN DIEGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan in focal segmental...
Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses
03 oct. 2018 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that presentations highlighting the design of the ongoing pivotal Phase 3 FORT Study of fosmetpantotenate...
aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors
10 avr. 2017 17h00 HE
|
aTyr Pharma Inc.
SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe,...
Robbins Arroyo LLP: Retrophin, Inc. (RTRX) Misled Shareholders According to a Recently Filed Class Action
22 oct. 2014 19h16 HE
|
Robbins LLP
SAN DIEGO and NEW YORK, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Retrophin, Inc. (Nasdaq:RTRX) has filed a federal securities...
RETROPHIN SHAREHOLDER ALERT - Andrews & Springer LLC is Investigating Retrophin, Inc. for Possible Violations of Securities Laws
16 juin 2014 08h00 HE
|
Andrews & Springer LLC
WILMINGTON, Del., June 16, 2014 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating the Board of...